Emerge Health

News

news

Posted 01-Dec-2017

ASACOL® (mesalazine) PBS Listing

EMERGE HEALTH PTY LTD, a specialty medicines company, today announced the PBS listing of ASACOL 800mg mesalazine enteric-coated tablets [AUST R 261420], effective as of the 1st of December 2017. ASACOL is indicated for the treatment of mild to moderate ulcerative colitis and maintenance of remission in adults. All hospital pharmacies ..

ASACOL® (mesalazine) PBS Listing Overview



Posted 02-Dec-2016

Transfer of Sponsorship of CLEVIPREX® from The Medicines Company Australia Pty Ltd

EMERGE HEALTH PTY LTD a specialty medicines company, today announced that it will be taking over the Sponsorship of CLEVIPREX® (clevidipine) effective as of the 6th of December 2016. Following the Transfer of Sponsorship there will be no change to the availability of CLEVIPREX for your hospital or patients. All hospital pharmacies will be ..

Transfer of Sponsorship of CLEVIPREX® from The Medicines Company Australia Pty Ltd Overview



Posted 26-Oct-2016

Daniele De Luca Tour

As part of Emerge Health’s commitment to further education and creating forums to discuss the latest research and topics in respiratory research and neonatal management of RDS (Respiratory Distress Syndrome), the company sponsored Professor Daniele De Luca to Australia as an international speaker. Prof. De Luca is currently the Medical Dir..

Daniele De Luca Tour Overview



Posted 22-Jun-2016

Emerge Health Supports HGSA 40th Annual Scientific Meeting

Emerge Health will be supporting the Human Genetics Society of Australia (HGSA) at the 40th Annual Scientific Meeting in Hobart, Australia from the 6th – 9th August. If you are attending the event, we will be at booth 11 so come over and say hello! The conference promises to be an exciting meeting with strong scientific content, covering v..

Emerge Health Supports HGSA 40th Annual Scientific Meeting Overview



Posted 18-Dec-2015

Emerge Health Christmas Trading Hours

From the 23rd of December 2015 to the 8th of January 2016, Emerge Health will not be operating during the normal business hours of 9:00AM to 5:00PM. If you wish to place an order during this period, please refer to the customer support hours below. 2015 December 23rd 9:00AM - 1:00PM December 24t..

Emerge Health Christmas Trading Hours Overview



Posted 27-Nov-2015

Emerge Health supports Hospital Pharmacists at SHPA's 41st Conference

Emerge Health will be supporting the Society of Hospital Pharmacists Australia (SHPA) Medicines Management National Conference again this year in Melbourne from the 3rd to 5th of December, as Exhibitors. If you are attending SHPA’s 41st Conference, please come and visit Emerge Health at Stand 39 to speak to us and take advantage of our limi..

Emerge Health supports Hospital Pharmacists at SHPA's 41st Conference Overview



Posted 17-Feb-2015

Carbaglu® (carglumic acid 200mg dispersible tablets) is now a TGA Registered Product

EMERGE HEALTH PTY LTD the exclusive distributor of Carbaglu® (carglumic acid 200mg dispersible tablets) in Australia is pleased to announce approval has been granted by the Therapeutic Good Administration (TGA) for the following indications: Hyperammonaemia due to N-acetylglutamate synthase primary deficiency Hyperammonaemia due to Org..

Carbaglu® (carglumic acid 200mg dispersible tablets) is now a TGA Registered Product Overview



Posted 02-Feb-2015

Emerge Health Appoints DHL Supply Chain Partner

Emerge Health Pty Ltd is pleased to announce that distribution of all products will be managed by Melbourne based DHL Supply Chain (Australia) Pty Ltd. DHL Supply Chain is a market leader in customer focused logistics services for the life science and research communities globally. With the ability to manage distribution of various product ..

Emerge Health Appoints DHL Supply Chain Partner Overview



Posted 07-Mar-2014

Emerge Health Partners With Chiesi Farmaceutici For Distribution Rights To Market Curosurf® (poractant alfa) in Australia

EMERGE HEALTH PTY LTD a specialty medicines company, today announced it has the exclusive marketing and distribution rights of Curosurf® in Australia. Curosurf® (poractant alfa) is indicated for the treatment (rescue) of Respiratory Distress Syndrome (RDS) in premature infants and for prophylactic use in infants at risk of RDS About Eme..

Emerge Health Partners With Chiesi Farmaceutici For Distribution Rights To Market Curosurf® (poractant alfa) in Australia Overview



Posted 01-Nov-2012

Emerge Health Supports Hospital Pharmacy at SHPA Conference, Canberra 2012

With its ever growing presence as a supplier to Hospital Pharmacy across Australia, Emerge Health will be attending the SHPA Conference in Canberra on Nov 1-3. Sponsoring the Conference as an exhibitor, Emerge Health will also launch two new innovative and exclusive hospital pharmacist tools. These two web enabled tools were developed on the f..

Emerge Health Supports Hospital Pharmacy at SHPA Conference, Canberra 2012 Overview



Posted 01-Feb-2012

New Partnership with Orphan Europe

Emerge Health announces a new partnership with Orphan Europe for exclusive distribution of products in Australia and New Zealand Australia and New Zealand News Emerge Health Pty Ltd (Emerge) is pleased to announce a new partnership with Orphan Europe (a division of the Recordati Group Italy), for the exclusive distribution in Australia..

New Partnership with Orphan Europe Overview